New Trial Suggests CV Benefit With EPA: RESPECT-EPA

Although the open-label trial has many limitations, it could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose eicosapentaenoic acid.

Related Keywords

Japan ,United States ,Japanese ,American ,Deepak Bhatt ,Pamr Taub ,Steve Nissen ,Hiroyuki Daida ,American Heart Association ,Juntendo University Graduate School Of Medicine ,Japan Heart Foundation ,Scientific Sessions ,Juntendo University Graduate School ,Medscape Cardiology ,Intervention Study ,Cleveland Clinic ,Secondary Prevention Efficacy ,Combination Therapy Statin ,Late Breaking Clinical Trials ,California San Diego School ,Japan Heart ,Cv ,Ardiovascular ,Lipids ,Ipid Management ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Angina ,Angina Pectoris ,Statin ,Lipid Lowering Drugs ,Rug Lipid Lowering ,Acute Coronary Syndrome Acs ,Cute Coronary Syndrome ,Cs ,Atrial Fibrillation ,F Atrial Fibrillation ,Thromboembolism ,Stroke ,Erebrovascular Accident ,Gva C ,